89 related articles for article (PubMed ID: 31558240)
1. Squamous Cell Carcinoma Transformation as a Possible Resistant Mechanism Against Pembrolizumab Plus Chemotherapy.
Kozuma Y; Toyokawa G; Shoji F; Yamazaki K; Kawauchi S; Momosaki S; Takeo S
J Thorac Oncol; 2019 Oct; 14(10):e238-e240. PubMed ID: 31558240
[No Abstract] [Full Text] [Related]
2. Acute Generalized Exanthematous Pustulosis Caused by the Combination of Pembrolizumab Plus Chemotherapy in a Patient With Squamous-Cell Carcinoma.
Matsubara T; Uchi H; Haratake N; Takamori S; Toyozawa R; Miura N; Yamaguchi M; Seto T; Takenoyama M
Clin Lung Cancer; 2020 Mar; 21(2):e54-e56. PubMed ID: 31874730
[No Abstract] [Full Text] [Related]
3. Extrinsic Upregulation of PD-L1 Induced by Pembrolizumab Combination Therapy in Patients with NSCLC with Low Tumor PD-L1 Expression.
Kunimasa K; Nakamura H; Nishino K; Nakatsuka SI; Kumagai T
J Thorac Oncol; 2019 Oct; 14(10):e231-e233. PubMed ID: 31558236
[No Abstract] [Full Text] [Related]
4. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Langer CJ; Gadgeel SM; Borghaei H; Papadimitrakopoulou VA; Patnaik A; Powell SF; Gentzler RD; Martins RG; Stevenson JP; Jalal SI; Panwalkar A; Yang JC; Gubens M; Sequist LV; Awad MM; Fiore J; Ge Y; Raftopoulos H; Gandhi L;
Lancet Oncol; 2016 Nov; 17(11):1497-1508. PubMed ID: 27745820
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.
Gadgeel SM; Stevenson JP; Langer CJ; Gandhi L; Borghaei H; Patnaik A; Villaruz LC; Gubens M; Hauke R; Yang JC; Sequist LV; Bachman R; Saraf S; Raftopoulos H; Papadimitrakopoulou V
Lung Cancer; 2018 Nov; 125():273-281. PubMed ID: 30429032
[TBL] [Abstract][Full Text] [Related]
7. Complete response of recurrent squamous cell carcinoma of the lung: dose the dose matter?
Shin S; Kim KJ; Lee YJ; Choi HJ; Kim H; Kim JH; Cho BC
J Thorac Oncol; 2009 Jan; 4(1):141-2. PubMed ID: 19096325
[No Abstract] [Full Text] [Related]
8. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer.
Mazieres J; Kowalski D; Luft A; Vicente D; Tafreshi A; Gümüş M; Laktionov K; Hermes B; Cicin I; Rodríguez-Cid J; Wilson J; Kato T; Ramlau R; Novello S; Reddy S; Kopp HG; Piperdi B; Li X; Burke T; Paz-Ares L
J Clin Oncol; 2020 Jan; 38(3):271-280. PubMed ID: 31751163
[TBL] [Abstract][Full Text] [Related]
9. Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib.
Wang F; Qin J; Xie F; Wu Q; Lu H
Lung Cancer; 2020 Feb; 140():118-120. PubMed ID: 31924369
[No Abstract] [Full Text] [Related]
10. Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
Hsu CL; Chen KY; Kuo SW; Chang YL
J Thorac Oncol; 2017 Jun; 12(6):e75-e76. PubMed ID: 28532567
[No Abstract] [Full Text] [Related]
11. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Vandormael K; Riccio A; Yang J; Pietanza MC; Brahmer JR
J Clin Oncol; 2019 Mar; 37(7):537-546. PubMed ID: 30620668
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab for non-small-cell lung cancer.
Sonpavde G
N Engl J Med; 2007 Mar; 356(13):1374; author reply 1374-5. PubMed ID: 17396304
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US.
Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Burke T
J Med Econ; 2018 Dec; 21(12):1191-1205. PubMed ID: 30188231
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US.
Insinga RP; Vanness DJ; Feliciano JL; Vandormael K; Traore S; Ejzykowicz F; Burke T
Curr Med Res Opin; 2019 Jul; 35(7):1241-1256. PubMed ID: 30649973
[No Abstract] [Full Text] [Related]
16. Real-World Experience With Pembrolizumab in Patients With Advanced Lung Cancer.
Peng TR; Wu TW
Am J Ther; 2019; 26(4):e537-e538. PubMed ID: 30946046
[No Abstract] [Full Text] [Related]
17. Tumor lysis syndrome and acquired ichthyosis occurring after chemotherapy for lung adenocarcinoma.
Honda K; Saraya T; Tamura M; Yokoyama T; Fujiwara M; Goto H
J Clin Oncol; 2011 Dec; 29(35):e859-60. PubMed ID: 22042943
[No Abstract] [Full Text] [Related]
18. Bevacizumab plus weekly paclitaxel with or without carboplatin for previously-treated non-squamous non-small cell lung cancer.
Hata A; Katakami N; Tanaka K; Takeshita J; Matsumoto T; Monden K; Nagata K; Masago K; Kaji R; Fujita S; Tachikawa R; Otsuka K; Otsuka K; Tomii K
Anticancer Res; 2014 Jan; 34(1):275-81. PubMed ID: 24403474
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety Results From a Phase II, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy for Advanced Squamous Cell Non-Small-Cell Lung Cancer.
Hirsch FR; Govindan R; Zvirbule Z; Braiteh F; Rittmeyer A; Belda-Iniesta C; Isla D; Cosgriff T; Boyer M; Ueda M; Phan S; Gandara DR
Clin Lung Cancer; 2017 Jan; 18(1):43-49. PubMed ID: 27461773
[TBL] [Abstract][Full Text] [Related]
20. Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
Levy BP; Giaccone G; Besse B; Felip E; Garassino MC; Domine Gomez M; Garrido P; Piperdi B; Ponce-Aix S; Menezes D; MacBeth KJ; Risueño A; Slepetis R; Wu X; Fandi A; Paz-Ares L
Eur J Cancer; 2019 Feb; 108():120-128. PubMed ID: 30654297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
